Nissay Asset Management Corp Japan trimmed its position in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) by 11.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 20,036 shares of the life sciences company’s stock after selling 2,711 shares during the quarter. Nissay Asset Management Corp Japan’s holdings in Illumina were worth $3,523,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently made changes to their positions in the company. HighPoint Advisor Group LLC raised its holdings in Illumina by 3.7% in the 4th quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock valued at $291,000 after buying an additional 80 shares during the last quarter. Elevation Wealth Partners LLC grew its holdings in Illumina by 52.5% during the 2nd quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock worth $43,000 after acquiring an additional 84 shares during the last quarter. Meeder Advisory Services Inc. increased its position in Illumina by 3.1% in the 1st quarter. Meeder Advisory Services Inc. now owns 2,822 shares of the life sciences company’s stock valued at $348,000 after acquiring an additional 85 shares during the period. Toronto Dominion Bank increased its position in Illumina by 0.3% in the 4th quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company’s stock valued at $4,407,000 after acquiring an additional 92 shares during the period. Finally, Panagora Asset Management Inc. raised its stake in shares of Illumina by 3.9% during the fourth quarter. Panagora Asset Management Inc. now owns 2,536 shares of the life sciences company’s stock valued at $333,000 after acquiring an additional 96 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.
Insider Activity
In related news, insider Scott M. Davies sold 615 shares of Illumina stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $200.00, for a total value of $123,000.00. Following the completion of the sale, the insider owned 20,338 shares of the company’s stock, valued at approximately $4,067,600. This trade represents a 2.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 138,379 shares of Illumina stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $228.89, for a total transaction of $31,673,569.31. Following the completion of the sale, the director directly owned 1,033,910 shares of the company’s stock, valued at approximately $236,651,659.90. The trade was a 11.80% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 1,799,688 shares of company stock worth $379,517,231 over the last quarter. 2.90% of the stock is currently owned by corporate insiders.
Analyst Ratings Changes
Check Out Our Latest Report on ILMN
Illumina Price Performance
ILMN stock opened at $213.63 on Tuesday. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. The company’s 50-day moving average is $195.10 and its 200-day moving average is $156.54. The stock has a market capitalization of $32.26 billion, a PE ratio of 39.86, a price-to-earnings-growth ratio of 3.03 and a beta of 1.44. Illumina, Inc. has a 1 year low of $88.00 and a 1 year high of $231.81.
Illumina (NASDAQ:ILMN – Get Free Report) last issued its earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The business had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. During the same period in the previous year, the company posted $1.19 EPS. The firm’s revenue was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Equities research analysts expect that Illumina, Inc. will post 5.36 EPS for the current fiscal year.
Illumina Company Profile
Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.
The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.
See Also
- Five stocks we like better than Illumina
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN – Free Report).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.
